Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.
D001904:Botulinum Antitoxin / Q000008:administration & dosage / Q000276:immunology; D001906:Botulism / Q000188:drug therapy*; D002487:Centers for Disease Control and Prevention, U.S.; D015507:Drugs, Investigational; D006801:Humans; D014481:United States
D001904:Botulinum Antitoxin; D015507:Drugs, Investigational